Journal of Carcinogenesis

Review Article

Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges

Subhamoy Dasgupta*[1,*], Srinivasa Srinidhi[2,*], Jamboor K. Vishwanatha[1]

[1]Department of Molecular Biology and Immunology, and Institute for Cancer Research, University of North Texas Health Science Center, Fort Worth, TX, [2]Texas College of Osteopathic Medicine University of North Texas Health Science Center 3500 Camp Bowie Blvd, Fort Worth, TX, USA

E-mail: sdasgupt@bcm.edu
*Corresponding author
*Equal Contribution

Published: 17 February, 2012
Journal of Carcinogenesis 2012, 11:4
This article is available from: http://www.carcinogenesis.com/content/11/1/4

Received: 24 October, 2011
Accepted: 01 December, 2011

Abstract

Prostate cancer is a leading cause of death among men in the United States, and currently early diagnosis and appropriate treatment remain key approaches for patient care. Molecularly prostate cancer cells carry multiple perturbations that generate malignant phenotype capable of uncontrolled growth, survival, and invasion-metastasis to other organs. These alterations are acquired both by genetic and epigenetic changes in tumor cells resulting in the activation of growth factor receptors, signaling proteins, kinases, transcription factors and coregulators, and multiple proteases required for the progression of the disease. Recent advances provide novel insights into the molecular functions of these oncogenic activators, implicating potential therapeutic targeting opportunities for the treatment of prostate cancer.

Keywords: Prostate cancer, oncogene, PI3K-Akt, proteases, signaling pathways, growth factor receptors

INTRODUCTION

Prostate cancer is a highly prevalent disease and leading cause of cancer related deaths in the Western World. National Cancer Institute (NCI) estimates that about ~240 890 American men will be diagnosed with prostate cancer in 2011 and approximately ~33 720 will die of the disease. It is the most prevalent tumor in men and despite increasing efforts at early detection, 10–20% of the cases present bone metastasis at diagnosis. Most men diagnosed with prostate cancer can survive the primary localized tumor; however, because of the widespread metastasis that are resistant to conventional treatment including improved surgical techniques, mortality rates remain extremely high. Development of prostate cancer is prevalently asymptomatic, and once symptoms are noticed, it usually implies an advanced disease stage. Metastatic dissemination of cancer cells consists of series of sequential interrelated steps that lead to spread of the disease to distant organs such as bone, lymph nodes, rectum, urinary bladder, and brain, which ultimately leads to death. So, it is critical to understand the mechanisms that drive prostate cells to become metastatic. Moreover, it is also important to diagnose the disease at an early stage so that proper therapy can be administered, for which we need a predictable biomarker. Thus, by understanding the molecular events in the pathogenesis of prostate cancer and detecting a reliable biomarker will offer improved diagnosis, prognosis, and therapy of the disease that will ultimately help us to eliminate prostate cancer.

Access this article online

Quick Response Code:

Website: www.carcinogenesis.com

DOI: 10.4103/1477-3163.93001

Tumorous growth in prostate can either be benign or malignant. Benign, nodular, paraurethral hyperplasia of the prostate (BPH) is one of the most prevalent disease of elderly American men. BPH can develop due to hormonal imbalance due to altered testosterone level, or may be stimulated by testosterone or dihydrotestosterone. Several growth factors may play important role in regulating epithelial and stromal cells in BPH.[1] In the presence of hormonal imbalance, the expression of the growth factor receptors are altered, which leads to increased cellular signaling and stromal cell proliferation. Nodular hyperplasia of the prostate is due to increased proliferation of glandular-epithelial compartment, with simultaneous mesenchymal stromal cell proliferation. This may lead to the alteration of the stromal unit, with inversion of the proliferation compartment, shift of luminal cells, thereby development of adenomatous hyperplasia. If this develops in the peripheral part of the prostate gland, it is termed as prostatic intraepithelial neoplasia (PIN).[1] Histopathologically PIN is regarded as the precursor of prostatic adenocarcinoma. PIN exists with more than 85% of cancer, and clinically it has a strong association with prostatic carcinoma.[2,3] A number of studies have identified differentially regulated genes that are expressed in neoplastic progression of prostatic progression. Differentially expressed genes are predicted to play key roles in prostate cancer development and may also serve as clinically useful biomarker for early detection and diagnosis. Although large sets of genes have been identified, few have been characterized in the molecular progression of the disease. In this review, we will focus on the advancements of crucial prostate cancer oncogenes, which have been established as potential target for therapy.

Growth factor receptors

Insulin growth factor

A number of growth factors have been shown to be implicated in the development of prostate cancer. One of the most studied growth factors in the process of promoting oncogenesis in prostate cancer is insulin-like growth factor (IGF). Although the IGF functions as an endocrine hormone, being predominantly secreted by the liver,[4] it can also act as an autocrine and paracrine hormone, whose local secretion may be a possible stimulus for cell growth in neoplasms.

IGF1 and IGF2 work via the same receptor, a transmembrane glycoprotein[5] with tyrosine kinase activity, IGF1R. Increased expression of IGF1 and IGF2 has been shown via immunohistochemistry to be a positive correlation with serum PSA over 10. Additionally, the same study discovered that IGF2 has a positive statistically significant correlation with Gleason's score.[6]

Epidemiologically, there is a significantly higher elevation serum concentration of IGF levels in patients with prostate cancer compared to normal.[7] The role of IGF in oncogenesis is evident through a number of different studies correlating decreased invasiveness with an inhibition of IGF. Remarkably, even the growth of metastatic prostate cancer tumor in the bone is inhibited by the administration of an IGF1 antibody, KM1468.[8] Reducing the hepatic production and secretion of IGF1 via disruption of growth hormone receptors significantly reduces the early carcinogenesis of prostate.[9]

IGF availability in the serum is regulated *in vivo* by IGF binding protein 3 (IGFBP3).[10] Several cell lines of prostate adenocarcinoma (22Rv1, PC-3, and DU-145) display increases concentrations of IGFBP3 in a dose-dependent manner via treatment with 5-FU; however, a significant decrease in the growth of PC3 was found attributable to a decreased bioavailability of IGF1[11] although IGFBP3 may play a role later in prostate adenocarcinoma migration, and cell-matrix adhesion in an IGF-1 independent mechanism.[12] It can also promote apoptosis in a poorly understood mechanism independent of IGF-1[13] making it debatable if the change in IGFBP3 levels really affected the cells in a IGF-1 independent or dependent manner. The significance of the role of IGFBP3 in regulating active IGF1 can be seen epidemiologically in Korean men revealing that prostate cancer sufferers more likely had lower serum levels of IGFBP3. The epidemiology remains controversial however with a different study suggesting that increased serum levels of IGFBP3 or IGF1 to IGFBP3 ratio are not correlated with likelihood of prostate cancer.[14]

IGF1 interacts with its respective intranuclear receptor, IGFR1. Through the receptor's tyrosine kinase activity[15] several downstream signaling pathways are activated, including the phosphatidylinositol 3-kinase (PI3K), AKT, TOR, S6 kinase, and mitogen-activated protein kinase (MAPK) pathways, by which the antiapoptotic and proneoplastic effects of insulin like growth factor 1 function.

IGF1R has been spotlighted as a major player in prostate carcinogenesis and a major player in possible pharmacologic interventions in prostate cancer. There is a plethora of data suggesting a significant relationship between the increased IGF1R activity and increased prostate carcinogenesis, while at the same time illustrating that inhibition of the pathway will result in the diminished tumor growth. Additionally, it has been shown that both IGF1R protein and mRNA is upregulated in primary prostate cancer, as opposed to benign prostatic hyperplasia.[16]

Reducing the expression of IGF1R via antisense RNA retards

tumor growth of prostate cancer cells.[17] IGF1R may be an essential player in facilitating the continued activity of the androgen receptor, well after castration has occurred. It has been shown that the IGF pathway is capable of inducing the activation of the androgen receptor in the absence of androgens,[18] or in facilitating its translocation into the nucleus, without androgens, although this activation of androgen receptor may rely on the assistance of several other proteins such as beta catenin.[19] The IGFR pathway via its actions on the PI3K/AKT pathway phosphorylates the androgen receptor inhibitor Foxo1.[20] In addition to the direct stimulation of the androgen receptor in an androgen independent pathway, it is apparent that IGF1 pathway may also up regulate proteins that are also up regulated by the androgen receptor. One possible candidate protein is survivin, which is an antiapoptotic caspase inhibitor, which has been shown to be androgen dependent, but can be up regulated in the absence of androgens by the presence of insulin growth factor.[21]

Although androgenic stimulation of the androgen receptor remains essential in stimulating growth of the prostate cells, it is important to note that it is possible for the prostate to continue having an activated androgen receptor, and tumor growth even following the lack of androgenic stimulation via castration. It has therefore been hypothesized that there must be some sort of androgen independent stimulation of the androgen receptor that may be at work in causing the prostate tumor growth. The IGF signaling pathway is a candidate pathway for this functionality. The inhibition of IGF1 signaling by antibody to IGF1R following castration reduced prostate tumor growth much more in androgen-dependent cells than it did mice that underwent castration alone.[22] Although there may be a drop in IGF signaling immediately after castration, the IGF1 signaling pathway remains active throughout the course of the disease.[23] Additionally, IGF1 signaling may also play an important role in migration and invasion in addition to encouraging proliferation and resistance against apoptosis through the possible stimulation of the metalloprotease MT1-MMP[24] and encouraging actin rearrangements in the cytoskeleton that may activate integrins and lead to the promigratory cell behavior.[25]

Wnt

The Wnt signaling pathway is another major of oncogenic signaling pathway involved in the carcinogenesis of prostate cancer. It is apparent that the Wnt pathway is important in the preliminary development of the prostate.[26] The Wnt/B catenin pathway is an important player in prostate oncogenesis, particularly in giving tumor cells their invasiveness. The suppression of Wnt signaling by an inhibitor of the pathway, WIF1, has been shown to significantly reduce the size of tumors in addition to reducing MMP2 and 9 in PC3 cells[27] in addition to increasing the expression of the epithelial metalloprotease, MMP7[28] Foxa2, which may be important in the local invasiveness of prostate cancer is increased by the Wnt signaling pathway. To further highlight the relevance of the Wnt pathway on invasiveness of prostate adenocarcinoma, a study revealed that CamKII, which is a transducer in the Wnt pathway, increases cytoskeletal remodeling and cell motility[29] that may possibly facilitate future tumor invasiveness. A Wnt family protein, Wnt11, confers increased invasiveness for both LNCaP and PC3 cell lines.[30]

Her-2/neu (ERBB2)

The Her2/neu protein is a notorious proto-oncogene that has been implicated in a number of different cancers, particularly in breast cancer and the target of a number of current and experimental therapies.[31] Her2/Neu is a transmembrane tyrosine kinase that is important in assisting differentiation and cell growth. Despite its major role in the diagnosis and treatment of breast cancer, Her2/Neu plays an important role in the understanding of prostate adenocarcinoma oncogenesis. Although Her2/Neu is not necessarily correlated with a Gleason's score,[32] patients suffering from metastatic prostate cancer were more likely to have higher levels of serum Her2/neu versus those with nonmetatstatic or localized disease[33] suggesting that Her2/Neu may be an important marker for advanced disease[34] or clinically worse outcomes;[35] however, Her2/Neu expression does not seem to be related to the Gleason score of the biopsy.[36]

Similar to the other major oncogenes discussed so far, Her2/Neu is capable of activating the androgen receptor in the androgen independent stage. Her2/Neu can promote survival of LNCaP cells through the Akt pathway, even in the absence of androgens. Interestingly, this effect can be halted by the addition of Dn-Akt, an inhibitor of Akt.[37] Additionally, Her2/neu can provide androgen independent activation of the AR via a pathway modulated by both MAPK and c-Jun,[38] which is also important in stabilizing the androgen receptor. This interaction between Her2/neu and the androgen receptor is regulated by an miRNA, miR-331-3p, the addition of which can inhibit both the downstream activation of PI3K/Akt signaling, in addition to reducing the AR-regulated PSA expression.[39] Additionally, Her2/Neu can, via PYK2, help facilitate the cell adhesion that allows for the tumor's metastatic potential.[40] Her2/Neu's relationship with the AR, however, is not universally accepted as LNCaP cells have decreased AR mRNA in addition to decreased AR and AR regulated PSA.[41]

Her2/Neu may also play an important role in the metastasis of prostate cancer into the bone. In patients with bone

metastases, Her2/Neu over expression is associated with a poorer prognosis.[42] As we have described previously, the receptor is also important in facilitating metastasis. The orthotropic transfection of Her2/Neu facilitates changes downstream that allow for the tumor's cell's increased metastatic capacity. A PC-3 cell line that was transfected with orthotropic Her2/Neu produced numerous metastases all over the abdomen, including the retroperitoneum and the kidney.[43] Molecularly, the Her2/Neu receptor is part of a signaling cascade that involves the downstream enhancement of Akt and MMP-9, whereby the cancer cell is allowed to penetrate the matrix and facilitate angiogenesis.[44]

Epidermal growth factor receptor

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is related to the ErbB2, and participates in several signaling cascade including Akt, MAPK, and STAT, whereby it plays an important role in tumor cell growth. Overexpression of EGFR is correlated with time to biochemical relapse[45] and the interference of EGFR with miRNA 28, does allow for increased apoptosis of prostate tumor.[46] Additionally, immunohistochemically speaking, higher association of EGFR was statistically correlated with a higher serum PSA. Additionally, the relevance of EGFR to prostate cancer oncogenesis can be further revealed by the fact that specimens with a diagnosis of Gleason's scores above 7 were significantly more likely to have co-expression of EGFR with an association Her2, c-erb-2[47]

There has been a plethora of studies regarding the targeting of EGFR in chemotherapeutics, in particular, the synthetic antibody Geftinib, which is currently marketed as an EGFR inhibitor for use in non small cell lung cancer. The knockout of EGFR via siRNA resulted in autophagosomes and in increased levels of calpain, a proapoptotic protein both of which are characteristic of apoptosis. Additionally, knocking down EGFR but not altering its tyrosine kinase activity made tumor cells more susceptible to adriamycin, which allowed for increased levels of caspase 3 and 7.[48]

EGFR seems to display a rather complicated interaction with androgens and the androgen receptor. Normally androgens are responsible for the down regulation of EGFR. In the cancer cell, however, the introduction of androgens may increase the levels of EGFR mRNA, and antibody mediated inhibition of EGFR prevented androgen mediated proliferation, although this remains debatable as another study revealed that EGFR was shown to have increased ubiquitination and degradation following activation of the androgen receptor.[49]

Phosphoinositide-3 Kinase/AKT

Phosphoinositide-3 Kinase (PI3K) is a critical mediator of multiple oncogeneic signaling pathways. PI3K is activated by the receptor tyrosine kinases generating PI3, 4P2, and PI3,4,5P3 (PIP3), which acts as secondary messengers triggering downstream signaling events. Most important PI3K downstream targets include Akt family of serine-threonine kinases, which are then recruited by PIP3 to the plasma membrane and phosphorylated by PDK1 kinase. Once phosphorylated, Akt is activated which then promotes cellular proliferation and survival by regulating several downstream targets. The most critical negative regulator of PI3K-Akt pathway includes PTEN, a phosphatase that has high specificity for lipid substrates.[50] In prostate cancer, PTEN is frequently lost resulting in hyperactive PI3K/Akt pathway promoting prostate cancer progression.

Somatic alterations in the *PTEN* gene have been identified in prostate cancer patients for both localized and metastatic disease. These include deletions, and inactivating missense and nonsense mutations in ~15% of primary tumors.[51] PTEN alterations are more common in metastatic cancers and studies have identified biallelic loss of PTEN in ~50% of metastatic hormone-refractory prostate cancer.[52] Genomic amplifications in AKT1 and AKT2 in prostate cancer are rarely found, however, loss of PTEN results in constitutively activated Akt which promotes tumor growth. Crucial downstream signaling cascade of PI3K/Akt include mTOR pathway that is deregulated by loss of function mutations in PTEN. Activated mTOR phosphorylates substrates critical for protein synthesis, including ribosomal subunit S6 kinase (S6K) and initiation factor 4E-binding protein 1(4E-BP-1) thereby activating protein translation and tumor growth.[53] Akt/mTOR-dependent stabilization of Hif1α transcription factor and increased expression of Hif1α target genes have been detected in PIN mouse models[54] that includes enzymes of the glycolytic pathway.

We have identified a novel gene *MIEN1* (previously referred to as C17orf37) highly overexpressed in prostate cancer, which modulates the Akt activity as a membrane bound adapter protein.[55] MIEN1 is post-translationaly modified by addition of prenyl groups that translocates the protein to the inner face of the plasma membrane.[56] Ectopic expression of MIEN1 activates Akt and cascades downstream signaling through NF-κB pathway upregulating expression of several migratory and invasive genes. MIEN1 may act as a scaffolding protein blocking PTEN binding to Akt; however, the exact mechanism is not known.

Targeting PI3K-Akt pathway to treat prostate cancer patients is an active area of research. Several small molecule inhibitors

have been developed that are currently undergoing clinical trials for prostate cancer therapy. mTOR inhibitor RAD001 (everolimus) is currently under clinical trials for castration resistant prostate cancer (CRPC) patients either alone or in combination with gefitinib. A new mTOR inhibitor AP23573 is currently in phase II clinical trials as a single agent treatment for CRPC patients. PI3K and Akt are also attractive drug targets for prostate cancer therapy, but despite serious efforts inhibitors targeting the kinase activity lack specificity.[57]

Proteases

The MMPs and promigration

Like the Wnt pathway, the MMPs are essential in facilitating the invasiveness of prostate cancer. These proteins are important in the degradation of the extracellular matrix, whereby the invasive prostate cancer cells can metastasize to distant site throughout the body [Figure 1]. Additionally, this protease activity, not only allows for cell migration, but also plays a role in facilitating angiogenesis, whereby the tumor in provided with nutrition allowing its continued proliferation. In bone metastases, the prostate metastatic tissue might allow for angiogenesis via the MMP9 derived from osteoclasts.[59] As such, the metalloproteases are particularly important players later on in prostate cancer, when the cancer is most invasive. Some of the MMPs have a higher expression with higher Gleason's scores.

The targeting of the zinc proteases has become a major spotlight in possible future chemotherapeutic interventions.[60] Of the many different members of the homologous MMP family, MMP 2, 7, and 9 in addition to



Figure 1: Multistep metastatic process of prostate cancer cells. The molecular basis of tumor progression depends on local invasion, intravasation, survival in the circulation, extravasation and colonization. Tumor cells secrete several factors including proteases like MMPs and plasmin which degrade extracellular matrix facilitating their migration and invasion. Tumors cells then intravasate through the endothelial lining of blood vessels into the circulation, and extravasate to distant organs like lymph nodes, bones and rectum. Prostate cancer cells then colonize and proliferate in foreign tissue thereby spreading the disease. (Taken from Dasgupta S, Ph.D thesis,[58])

MT1MMP are the most relevant in terms of relevance in prostate adenocarcinoma metastasis. There is a particularly higher level of MMP9 expression in prostate cancer compared with other cancers. While the lack of MMP 2, 7, or 9 in CR2-Tag mice all can lead to reduced tumor vascularity, the dearth of MMP2 also conferred decreased lung metastasis and increased survival, while interestingly, the lack of MMP 9 lead to increased perivascular invasion, in addition to reduced vessel size,[61] highlighting the unique functions that the different members of the MMP family have. Several of the major metalloproteases related to prostate adenocarcinoma, namely MMP 2, 9, and MT1MMP are inhibited by the DNA enzyme Dz13, which reduced tumor growth of PC3 cells.[60]

MMP 9

MMP 9 is a major player in prostate adenocarcinoma invasiveness. Pathologically speaking, higher levels of matrix metalloproteinase 9 as revealed by DAB staining, is correlated with higher Gleason's score, with 94.1% of cancer cell expressing MMP9 in the cytosol. It is apparent, therefore, that MMP9 expression intracellularly is directly correlated with a tissue Gleason's score.[62] With MMP-9 there is a correlation between an increase in MMP9 expression and the loss of PDEF, a possible inhibitor of MMP9, the loss of which results in a more aggressive phenotypic prostate cancer,[63] and to further confirm the relationship of aggressiveness with MMP9, downstream silencing of MMP-9 *in vivo* reduces the amount of metastasis of prostate cancer.[64] Normally, proMMP9 is in complex with tissue inhibitor of metalloproteinase (TIMP), preventing its immediate action. In the case of the neutrophils, however, lies an exception to this rule, releasing proMMP9 without its inhibitor, TIMP.[65]

MMP 7

The elevated expression of MMP7 in both the serum and resected prostate tissue is associated with a poorer prognosis[66] most likely due to the more invasive phenotype that increased levels of MMP7 confers. Although there has not been a published correlation between the expression of MMP7 and Gleason's score, a study investigating the serum levels of various MMPs in relation to the invasiveness of the prostate cancer, found that individuals with distant metastases, circulating serum MMP7 was significantly elevated, suggesting that MMP7 is a protein particularly more relevant in facilitating prostate cancer's distant metastases.[66] The applicability of such techniques has been shown through a number of different studies. One possible protein that MMP7 may interact with is a metalloproteinase regulator, E1AF, which is correlated with a more metastatic phenotype in prostate adenocarcinomas.[67] An additional role for MMP7 in prostatic adenocarcinoma can be seen in bone metastases. The secretion of MMP7 by both osteoclasts and the tumor

cells allows for the solubilization of osteoblast RANKL, which activates osteoclasts and tumor mediated osteolysis.[68]

MMP 2

MMP2 is another major metalloproteinase, whose activity is important in the invasiveness and metastasis of prostate cancer. Its expression and upregulation is associated with Rho mediated activation of Pyk2, FAK, MAPK, and Akt.[69] Similar to the other MMPs discussed polymorphisms in *MMP2* gene is correlated with a higher Gleason's score.[70] In a study investigating the immunohistochemistry with the Gleason's score of various MMPs, it was found that the tissues that observed the highest level of MMP2 expression, also had the highest grade prostate cancer, as determined by their Gleason's score, scores between 8 to 10, suggesting MMP2's possible oncogenic role in prostate cancer.[71] Several studies have found many different influences on the expression of MMP2. In WPMY-1 cell stroma, ER stimulation either by estradiol, or by an agonist of the receptor increased the expression of MMP2 in the stroma indirectly via increased production of TGF-β, the inhibition of which yielded MMP2 levels comparable to that of the control.[72] Cyclin A1 may also play a role in influencing MMP2 production, in that areas of prostate tumor tissues with high expression of cyclin A1 are correlated with high expression of MMP2 and cells over expressing cyclinA1 also had statistically higher levels of MMP2.[73]

Transcription factors and coactivators

TMPRSS2-ERG

Recurrent genomic rearrangement in prostate cancer results in the fusion of androgen regulated gene *TMPRSS2* to *ERG*, which encodes an oncogenic transcription factor ETS. ETS family of transcription factors can bind specifically to DNA sequence 5′-GGA(A/T)-3′ in the promoter of genes and thus can regulate expression of genes involved in different pathways including proliferation, migration, and oncogenesis. Expression of TMPRSS2-ERG fusion transcript has been found in the early stages of prostate carcinogenesis prevalent in the low-grade prostate intraepithelial neoplasia (PIN).[74] FISH analysis has also confirmed 16–20% of ERG rearrangements in high grade PIN,[75] suggesting TMPRSS2-ERG an early event in prostate carcinogenesis. However, certain studies have identified increased ERG and ETV1 expression in metastatic prostate cancer both in androgen-dependent and castration-resistant disease,[76-78] suggesting *ETS* gene fusions can be maintained in advanced disease.

ETS gene perturbations in prostate cancer primarily involve fusions with androgen-activated genes and majority of studies have focused on mechanistic role of the fusion genes in carcinogenesis. In cultured prostate cancer cells androgen treatment induces ERG expression in cell lines harboring TMPRSS2-ERG fusion,[76] but not in androgen insensitive cells carrying the fusion gene.[79] Additional fusion partners have been identified for ETV1, ETV4, and ETV5 that includes TMPRSS2(21q22), SLC45A3(1q32), HERV-K(22q11.23), HERV-K17(17p13.1), FOXP1(3p13), C15orf21(15q21.1), HNRPA2B1(7p15), KLK2(19q13.33), CANT1(17q25.3), DDX5(17q24.1). Most of these translocation partners contribute to androgen inducible sequences, except C15orf21 which is repressed by androgen treatment and HNRPA2B1 insensitive to androgens.[76,80] Thus, differential androgen responsiveness driving *ERG* gene fusion could affect androgen ablation therapy in prostate cancer patients, and may provide resistance to androgen withdrawal therapy.

Aberrant expression of ETV1 in prostate cancer cells results in increased invasiveness, a phenotype associated with malignant progression of the disease.[81] Transgenic mice overexpressing prostate specific ETV1 develops mouse PIN[82] consistent with the clinical observations in human patients, although it failed to develop tumor thus suggesting gene fusions are early events in prostate tumorigenesis. However, other investigators demonstrated knockdown of TMPRSS2-ERG expression resulted in reduced cellular proliferation and tumor growth in nude mice, suggesting ERG and ETV1 as potential therapeutic target.[83,84]

Several strategies have been used to block the *ETS* gene function including dominant negative mutants, antisense, and RNAi knockdown that were effective *in vitro* but less so *in vivo*.[85] Other approaches include inhibiting modulators of ETS transcription factors such as upstream signaling kinases and also downstream targets of ERG protein to block its activity.[86] Discovery of estrogen, progesterone, retinoic acid pathway alterations in nonandrogen responsive prostate cancers containing *ETS* gene rearrangements, suggests additional drug targets.[87]

Understanding the mechanisms of *ETS* gene translocations in prostate cancer has certainly provided important breakthrough about the disease. Clinically however the prognostic importance of *ETS* gene rearrangement is still controversial and additional studies are needed to identify and verify different variants of translocations. Furthermore, differential regulatory networks that drives ETS oncogenic rearrangements in prostate cancer with respect to androgen signaling need to be elucidated. This will provide additional benefits in treating the disease for both androgen responsive and castration resistant metastatic prostate cancer patients. Discovery of alternative estrogen signaling pathway signature genes also provide potential clues to elucidate mechanism of *ETS* gene activation in androgen insensitive cases.

MYC

One of the most commonly studied oncogene in prostate cancer pathogenesis is MYC, a regulator gene that codes for transcription factor. MYC is thought to regulate 15% of all genes in humans and is located in the human genome on chromosome 8q24 amplicon that is frequently amplified in prostate cancer patients. FISH analysis identified MYC overexpression in ~9% of primary prostate tumors but ~75% in advanced prostate cancer patients.[88] In a separate study, using comparative genomic hybridization investigators detected gain of the 8q region in 72.5% of cases whereas only 29% of them had genomic amplification as identified by FISH.[89] MYC overexpression has also been correlated with FOXP3 downregulation, and deletion of FOXP3 in human primary prostate cells resulted in concomitant increased MYC mRNA and protein level. At molecular level, FOXP3 binds to the promoter region of MYC and repress its transcription, and hence loss of FOXP3 increased MYC expression in prostate cancer patients.[90]

In vitro overexpression of MYC by viral transduction transformed prostate epithelial cells and immortalizes the cells in single step that were sufficient to generate tumors with increased proliferative capacity. Genetically engineered mouse models overexpressing MYC have been developed which uses either modified rat probasin promoter to drive MYC expression known as LOW-MYC or ARR_2/probasin promoter known as Hi-MYC.[82] These mouse models develop PIN and progress to invasive adenocarcinomas; however, the kinetics of tumor progression is different.

Several important MYC target genes, commonly known as MYC signature, have been identified which regulates numerous pathways involved in prostate cancer progression and metastasis. MYC regulates the transcription of these signature genes directly or indirectly in prostate cancer cells. One of the most well studied MYC downstream target gene includes PIM1, a serine/threonine kinase which has been identified to be frequently upregulated in subset of prostate cancers with poor clinical outcome.[91,92] *In vitro* and *in vivo* studies indicated that PIM1 alone is insufficient or weak to transform prostate cells, but in combination with MYC overexpression has increased proliferative rate. PIM1 also enhances the MYC transcriptional activity by directly phosphorylating histone H3 at MYC binding sites thereby enhancing transcription of MYC signature genes.[93] Another corollary experiment by inhibition of MYC resulted in reduced tumorigenicity of PIM1 overexpressing prostate cancer cells, validating the functional cooperation of the two proteins. NKX3.1 is a pleiotropic transcription factor that is involved in prostate gland development and morphogenesis, but lost during cancer pathogenesis and progression.[94] However, some studies have detected NKX3.1 expression in high grade invasive and metastatic prostate cancer patients.[95] In MYC transgenic prostate cancer mouse models, loss of NKX3.1 have been observed with the development of adenocarcinoma, suggesting MYC can repress NKX3.1 expression. This suggests oncogenic activation of MYC can block tumor suppressor protein resulting in the pathogenesis of prostate cancer.

Several therapeutic strategies have been used to target MYC and its signature genes in prostate cancer. Antisense oligonucleotides specifically designed to target MYC mRNA have been shown to reduce MYC protein resulting in reduced nuclear entry and decreased stability of the protein. *In vivo* studies utilizing mouse xenografts, MYC antisense oligonucleotides reduced tumor growth by suppressing tumor cell proliferation and increased animal survival.[96] One particular antisense with modified oligomer diamidate moroholino directed against MYC showed promising efficacy in phase I clinical trials with limited side effects and toxicity. These studies suggest antisense therapeutic approach targeting MYC may be beneficial for cancer treatment.

Another therapeutic approach utilizing cardiac glycosides to target MYC has shown promising effects in prostate cancer development. Both *in vivo* and *in vitro* studies demonstrated the antitumor potential of cardiac glycosides, particularly synthetic cardnolide UNBS1450 that blocks several MYC signature genes and inducing apoptosis.[97] This compound also showed reduced toxicity in normal cells; however, exact mechanism of its action is poorly understood.

Oncogenic transcriptional coactivators

Transcription factors and nuclear receptors bind to coregulatory molecules (coactivators or corepressors) that directly or indirectly regulate the transcription by recruiting several proteins to build the transcription complex at the target gene promoter. The most important nuclear receptor in context of prostate cancer is AR, which belongs to the large nuclear receptor superfamily of ligand activated transcription factor. In the absence of hormone, AR is located in the cytoplasm bound to heat shock proteins (hsp) but upon hormone induction dissociates from the hsp protein complex, dimerizes and translocates to the nucleus. AR dimer binds to specific DNA sequences known as androgen response elements (ARE) and recruits series of coactivator molecules necessary for chromatin remodeling and transcriptional complex. Large number of AR coactivators have been identified that are known to the potentiate AR activity,[98] of which steroid receptor coactivators (SRCs) have been studied extensively.

SRCs also known as Nuclear Receptor Coactivators (NCOA) consists of three homologous proteins SRC-1, SRC-2 and SRC-3 comprising the p160 SRC family. SRCs have three distinct structural domains that include most conserved region bHLH-PAS for protein–protein interaction, central nuclear receptor interacting domain containing three LXLL motifs, and C-terminal two transcriptional activation domains (AD1 and AD2). In addition to interacting with nuclear receptors, SRCs coactivates other transcription factors including NF-κB, STATs, HIF1, and Smads. Along with these transcription factors, SRCs have been found to be highly overexpressed or amplified in prostate cancer. Studies have shown SRC-1 messenger and protein expression positively correlates with prostate tumor grades; however, frequency of SRC-1 gene amplification in prostate cancer patients is less. SRC-1 can enhance AR-dependent growth of prostate cancer cells in culture, and knockdown of SRC-1 can significantly reduce growth of LNCaP cells. However, in AR-negative PC-3 and DU-145 cells SRC-1 has minimal effect, suggesting SRC-1 promotes prostate cancer growth by enhancing AR function. Expression of SRC-2, another member of SRC family has been found to be increased in prostate cancer and correlates positively with grade and stage of cancer. Recently, integrative genomic profiling has identified SRC-2 to be highly overexpressed in prostate cancer patients and has been classified as an oncogene in prostate cancer pathogenesis. Out of 218 prostatic tumors, 8% of primary tumors and 37% of metastatic tumors showed gain in SRC-2 expression.[99] Microarray analysis also confirmed increased expression of SRC-2 correlated with tumor proliferation and inhibition of apoptosis. Prostate cancer patients who underwent ADT, showed increased expression of SRC-2, and *in vitro* studies confirmed that high levels of androgen can repress SRC-2 expression, suggesting androgen ablation therapy can lead to increased SRC-2 in prostate cancer patients. Functionally, SRC-2 acts as potent transcriptional coactivator of AR, thereby modulating expression of AR target genes in both androgen dependent and castration resistant prostate cancer (CR-CaP) cells.[100,101] SRC-3 expression has been found to be increased in 38% of prostate cancer patients and its expression positively correlates with disease recurrence.[102] Mechanistically, SRC-3 regulates Akt-mTOR growth promoting pathways in prostate cancer cells and silencing of SRC-3 reduces tumor proliferation both *in vitro* and *in vivo*.[103,104] Functional role of SRC-3 was also evaluated in spontaneous TRAMP mouse models of prostate cancer, in which SRC-3 expression was higher in the advanced stages of the disease. SRC-3 gene deletion significantly increased TRAMP mice life expectancy suggesting SRC-3 inhibition may be an attractive therapeutic strategy for prostate cancer patients.[105]

Although several strategies have been used to silence SRCs to study their role in prostate cancer, effective inhibitors targeting the coactivators are still lacking. Disrupting the androgen receptor-SRC interaction using small molecule inhibitors or peptides may be a possible strategy along with conventional direct targeting of the coactivators using small molecules for prostate cancer therapy.

CONCLUDING REMARKS AND FUTURE PERSPECTIVE

Over the last two decades increased research efforts to understand the basic nature of prostate cancer biology has advanced our understanding about the disease. However, a number of fundamental questions concerning the heterogeneity of the disease, resistance to prevailing therapies, and therapeutic opportunities for advanced metastatic prostate cancer will be the prime focus for prostate cancer researchers. Technological advances to define the intricate details and molecular circuits within tumor cell and tumor microenvironment will identify prospective targets for prostate cancer.

Recent research has succeeded in implicating several oncogenic activations, either through genomic or nongenomic pathways, to neoplastic progression of prostate cancer cells



Figure 2: Cellular localization of various oncogenes and their signaling network promoting growth and survival of prostate cancer cells. Overexpressed growth factor receptors on ligand binding activate PI3K which converts PIP2 to PIP3. Phosphoinositide dependent kinase (PDK1) then binds to PIP3 and phosphorylate Akt. In prostate cancer, loss of PTEN, a lipid phosphatase responsible for converting PIP2 back to PIP3 favors in constitutively activated Akt which then phosphorylates and activates broad range of transcription factors including AR. Activated AR translocates to the nucleus and recruits general transcription factors, coativators (SRC), and other transcription machinery at the target gene promoter enhancing growth, survival and invasiveness. Fused oncogenes like ERG, an AR target gene can also upregulate expression of several genes promoting prostate cancer progression.

[Figure 2]. These hyperactive oncogenes confer metabolic and growth promoting advantages to tumor cells, which differ enormously within patient population. Understanding the genetic nature of prostatic tumor will be important for effective personalized treatment opportunity for prostate cancer patients. Growing concern lies in understanding the metastatic potential of primary prostatic tumor and ways to distinguish the lethal from dormant tumor subtype. Metastasis research over the years has identified several important molecules in the regulation of biological activities of tumor cell invasion and migration. Detailed understanding has identified potential oncogenes and their functional activities that provide prostate tumor cells invasive and migratory power to cross the primary tumor site and colonize at a distant organ. We hope that with this rapid pace of discovery continued with simultaneous translation of basic findings to clinical arena will offer us effective ways to treat and finally eliminate prostate cancer.

ACKNOWLEDGMENTS

We apologize to the many investigators whose valuable contributions to prostate cancer research were not cited due to space restrictions. SD was a Department of Defense Prostate Cancer Predoctoral Fellow supported by grant PC081282. JKV was supported in part by a grant from the National Center on Minority Health and Health Disparities (MD001633). This work was in part supported by an award from the National Center for Complementary and Alternative Medicine (Award No. 5T35AT004388-02).

REFERENCES

1. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, *et al*. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-25.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, *et al*. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
3. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004;4:327-36.
4. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
5. Sayeed A, Alam N, Trerotola M, Languino LR. Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins. J Cell Physiol 2012;227:751-8.
6. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, *et al*. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade. Hum Pathol 2005;36:1186-96.
7. Wolk A, Mantzoros CS, Andersson SO, Bergström R, Signorello LB, Lagiou P, *et al*. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-5.
8. Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, *et al*. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64:6252-8.
9. Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, *et al*. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 2005;146:5188-96.
10. Safarinejad MR, Shafiei N, Safarinejad S. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Growth Horm IGF Res 2011;21:146-54.
11. Kawabata R, Oie S, Takahashi M, Kanayama H, Oka T, Itoh K. Up-regulation of insulin-like growth factor-binding protein 3 by 5-fluorouracil (5-FU) leads to the potent anti-proliferative effect of androgen deprivation therapy combined with 5-FU in human prostate cancer cell lines. Int J Oncol 2011;38:1489-500.
12. Massoner P, Colleselli D, Matscheski A, Pircher H, Geley S, Jansen Dürr P, *et al*. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 2009;16:795-808.
13. Shahjee H, Bhattacharyya N, Zappala G, Wiench M, Prakash S, Rechler MM. An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm IGF Res 2007;18:188-97.
14. Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, *et al*. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan. Asian Pac J Cancer Prev 2009;10 Suppl:57-61.
15. Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urol Oncol 2011. [In Press]
16. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62:2942-50.
17. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Antisense RNA to the type 1 insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A 1996;93:7263-8.
18. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, *et al*. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Eur Urol 1995;27 Suppl 2:45-7.
19. Verras M, Sun Z. Beta-catenin is involved in insulin-like growth factor 1-mediated transactivation of the androgen receptor. Mol Endocrinol 2005;19:391-8.
20. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H, *et al*. Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor. J Biol Chem 2007;282:7329-38.
21. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005;24:2474-82.
22. Plymate SR, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, *et al*. An antibody targeting the type 1 insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007;13:6429-39.
23. Turney BW, Turner GD, Brewster SF, Macaulay VM. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression. BJU Int 2011;107:1488-99.
24. Sroka IC, McDaniel K, Nagle RB, Bowden GT. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Prostate 2008;68:463-76.
25. Marelli MM, Moretti RM, Procacci P, Motta M, Limonta P. Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol 2006;28:723-30.
26. Kharaishvili G, Simkova D, Makharoblidze E, Trtkova K, Kolar Z, Bouchal J. Wnt signaling in prostate development and carcinogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:11-8.
27. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, *et al*. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol Cancer 2010;9:162.
28. Yu X, Wang Y, DeGraff DJ, Wills ML, Matusik RJ. Wnt/b-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011;30:1868-79.
29. Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, *et al*. Novel

role for Wnt/Ca2+ signaling in actin cytoskeleton remodeling and cell motility in prostate cancer. PLoS One 2010;5:e10456.
30. Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, *et al*. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 2010;9:55.
31. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010;2:213-26.
32. Mofid B, Jalali Nodushan M, Rakhsha A, Zeinali L, Mirzaei H. Relation between HER-2 gene expression and Gleason score in patients with prostate cancer. Urol J 2007;4:101-4.
33. Osman I, Mikhail M, Shuch B, Clute M, Cheli CD, Ghani F, *et al*. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression. J Urol 2005;174:2174-7.
34. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006;13:1197-201.
35. Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, *et al*. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysiso. J Urol 2010;184:842-50.
36. Mofid B, Jalali Nodushan M, Rakhsha A, Zeinali L, Mirzaei H. Relation between HER-2 gene expression and Gleason score in patients with prostate cancer. Urol J 2007;4:101-4.
37. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, *et al*. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60:6451-5.
38. Mukherjee R, McGuinness DH, McCall P, Underwood MA, Seywright M, Orange C, *et al*. Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer. Br J Cancer 2011;104:1920-8.
39. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 2009;284:24696-704.
40. Yuan TC, Lin FF, Veeramani S, Chen SJ, Earp HS 3rd, Lin MF. ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. Oncogene 2007;26:7552-29.
41. Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP. Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res 2009;69:5202-9.
42. Nishio Y, Yamada Y, Kokubo H, Nakamura K, Aoki S, Taki T, *et al*. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Urology 2006;68:110-5.
43. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, *et al*. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996;28:73-83.
44. Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfil RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res 2008;6:446-57.
45. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, *et al*. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011;11:31.
46. Addepalli MK, Ray KB, Kumar B, Ramnath RL, Chile S, Rao H. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther 2010;17:252-9.
47. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, *et al*. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
48. Xu S, Weihua Z. Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate 2011;71:1216-24.
49. Mukherjee B, Mayer D. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells. Int J Oncol 2008;33:623-9.
50. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, *et al*. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 1997;94:9052-7.
51. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005;24:7465-74.
52. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, *et al*. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
53. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
54. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003;4:147-58.
55. Dasgupta S, Wasson LM, Rauniyar N, Prokai L, Borejdo J, Vishwanatha JK. Novel gene C17orf37 in 17q12 amplicon promotes migration and invasion of prostate cancer cells. Oncogene 2009;28:2860-72.
56. Dasgupta S, Cushman I, Kpetemey M, Casey PJ, Vishwanatha JK. Prenylated c17orf37 induces filopodia formation to promote cell migration and metastasis. J Biol Chem 2011;286:25935-46.
57. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010;291:1-13.
58. Dasgupta S. Novel Gene C17ORF37 in Prostate Cancer Progression and Metastasis. Fort Worth, Tx: University of North Texas Health Science Center. Available from: http://www.digitalcommons.hsc.unt.edu/theses/100. [Last accessed on 2010].
59. Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment. Mol Cancer Res 2010;8:459-70.
60. Tan ML, Choong PF, Dass CR. Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours. Cancer Cell Int 2010;10:9.
61. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y, *et al*. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010;70:2224-34.
62. Trudel D, Fradet Y, Meyer F, Têtu B. Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis. Human Pathol 2010;41:1694-701.
63. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, *et al*. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: regulation of MMP 9 by PDEF. Mol Cancer 2010;9:148.
64. Wang Q, Diao X, Sun J, Chen Z. Regulation of VEGF, MMP-9, and metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 2011;35:897-904 .
65. Bekes EM, Schweighofer B, Kupriyanova TA, Zajac E, Ardi VC, Quigley JP, *et al*. Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation.. Am J Pathol 2011;179:1455-70.
66. Szarvas T, Becker M, Vom Dorp F, Meschede J, Scherag A, Bánkfalvi A, *et al*. levated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int J Cancer 2011;128:1486-92.
67. Maruta S, Sakai H, Kanda S, Hayashi T, Kanetake H, Miyata Y. E1AF expression is associated with extra-prostatic growth and matrix metalloproteinase-7 expression in prostate cancer. APMIS 2009;117:791-6.
68. Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, *et al*. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005;7:485-96.
69. Iizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S, *et al*. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008;68:7613-20.
70. dos Reis ST, Villanova FE, Andrade PM, Pontes J Jr, de Sousa-Canavez JM, Sañudo A, *et al*. Matrix metalloproteinase-2 polymorphism is associated with prognosis in prostate cancer. Urol Oncol 2010;28:624-7.
71. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996;8:69-75.
72. Yu L, Wang CY, Shi J, Miao L, Du X, Mayer D, *et al*. Estrogens promote invasion of prostate cancer cells in a paracrine manner through up-regulation of matrix metalloproteinase 2 in prostatic stromal cells. Endocrinology 2011;152:773-81.
73. Wegiel B, Bjartell A, Tuomela J, Dizeyi N, Tinzl M, Helczynski L, *et al*. Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis. J Natl Cancer Inst 2008;100:1022-36.
74. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster CS, *et al*. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene

2007;26:2667-73.
75. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, *et al*. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14:3380-5.
76. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, *et al*. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
77. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, *et al*. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-10.
78. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, *et al*. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
79. Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, *et al*. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007;9:200-6.
80. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009;6:429-39.
81. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, *et al*. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-9.
82. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, *et al*. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38.
83. Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, *et al*. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol 2007;21:1835-46.
84. Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, *et al*. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008;27:5348-53.
85. Oikawa T. ETS transcription factors: possible targets for cancer therapy. Cancer Sci 2004;95:626-33.
86. Janknecht R. Regulation of the ER81 transcription factor and its coactivators by mitogen- and stress-activated protein kinase 1 (MSK1). Oncogene 2003;22:746-55.
87. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, *et al*. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008;10:177-88.
88. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin C, *et al*. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1995;1:11-8.
89. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
90. Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, *et al*. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009;16:336-46.
91. He HC, Bi XC, Dai QS, Wang SS, Wei HA, Zhong WD, *et al*. Detection of pim-1 mRNA in prostate cancer diagnosis. Chin Med J (Engl) 2007;120:1491-3.
92. Valdman A, Fang X, Pang ST, Ekman P, Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004;60:367-71.
93. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007;9:932-44.
94. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, *et al*. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62:2999-3004.
95. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, *et al*. NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 2010;34:1097-105.
96. Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, *et al*. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 1997;50:1007-15.
97. Van Quaquebeke E, Mahieu T, Dumont P, Dewelle J, Ribaucour F, Simon G, *et al*. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 2007;50:4122-34.
98. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr Rev 2002;23:175-200.
99. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, *et al*. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
100. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE 3rd, Erdem H, *et al*. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006;66:10594-602.
101. Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol 2008;617:245-55.
102. Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 2001;85:1928-36.
103. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, *et al*. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005;65:7976-83.
104. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 2003;23:7742-55.
105. Chung AC, Zhou S, Liao L, Tien JC, Greenberg NM, Xu J. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice. Cancer Res 2007;67:5965-75

How to cite this article: Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges. J Carcinog 2012;11:4.

Source and Support: Department of Defense (PC081282), National Center on Minority Health and Health Disparities (MD001633), National Center for Complementary and Alternative Medicine (5T35AT004388-02) **Conflict of Interest:** None declared.

AUTHOR'S PROFILE

Dr. Subhamoy Dasgupta, Department of Molecular Biology and Immunology and Institute for Cancer Research University of North Texas Healths Science Center Fort Worth, TX

Dr. Jamboor K. Vishwanatha, Department of Molecular Biology and Immunology, and Institute for Cancer Research, University of North Texas Health Science Center 3500 Camp Bowie Blvd Fort Worth, TX

Mr. Srinivasa Srinidhi, Texas College of Osteopathic Medicine University of North Texas Health Science Center Fort Worth, TX